Bicara Therapeutics Announces $108M Series B Financing to Advance Dual-Action Biologics for Cancer

Cambridge, MA, March 6, 2023 (Business Wire) -- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable anti-tumor response, today announced that it completed an oversubscribed $108 million Series B financing to advance its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.

Read full article here.